Table 1.

Summary table of different pre-clinical and clinical stages anti-thrombotic aptamers.

Aptamer	Type	Target	Developer	Evaluation Stages	Reference
ARC-1779	DNA	Von Willebrand Factor	Archemix	Phase II	[23]
Rn-DsDsDs-44	Unnatural DNA	Von Willebrand Factor	TagCyx Biotechnologies, RIKEN Center for Life Science Technologies	Pre-clinical	[18]
DTRI-031	RNA *	Von Willebrand Factor	Duke Medical Center	Pre-clinical	[24]
NU172	DNA	IIa	ARCA Biopharm	Phase II	[25,26]
HD22	DNA	IIa	University of Bonn	Pre-clinical	[27]
HD1-22	DNA	IIa	University of Bonn	Pre-clinical	[27]
RE31	Modified DNA	IIa	Polish Academy of Sciences	Pre-clinical	[28]
M08	DNA	IIa	The University of Tokyo	Pre-clinical	[29]
ThAD	DNA	IIa	Arizona State University	Pre-clinical	[30]
R9d14t	RNA *	II/ IIa	Duke Medical Center	Pre-clinical	[31]
REG1	RNA *	IXa	Regado Biosciences	Phase III	[32,33,34]
REG2	RNA *	IXa	Regado Biosciences	Phase I	[35]
11F7t	RNA *	Xa	Duke Medical Center	Pre-clinical	[36]
FELIAP	DNA	XIa	McMaster University, Canadian Blood Services Thrombosis and Atherosclerosis Research	Pre-clinical	[37]
11.16	RNA *	XIa	Duke Medical Center	Pre-clinical	[38]
12.7	RNA *	XIa	Duke Medical Center	Pre-clinical	[38]
R4cXII-1	RNA *	XII/XIIa	Duke Medica Center	Pre-clinical	[39]
Kall1-T4	RNA *	Kallikrein	Duke Medical Center	Pre-clinical	[40]

* Note: RNA aptamers contain fluoro-modified cytosine and uracil nucleotides. Each Roman numeral represents the corresponding clotting factor.